Adiponectin inhibits oxidized low density lipoprotein-induced increase in matrix metalloproteinase 9 expression in vascular smooth muscle cells

被引:0
作者
Saneipour, Maryam [1 ]
Ghatreh-Samani, Keihan [1 ]
Heydarian, Esfandiar [1 ]
Farrokhi, Effat [2 ]
Abdian, Narges [2 ]
机构
[1] Shahrekord Univ Med Sci, Clin Biochem Res Ctr, Shahrekord, Iran
[2] Shahrekord Univ Med Sci, Cellular & Mol Res Ctr, Shahrekord, Iran
关键词
Matrix Metalloproteinase 9; Adiponectin; Oxidized Low Density Lipoprotein;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: High expression of matrix metalloproteinase 9 (MMP9) during vascular injury and inflammation plays an important role in atherosclerotic plaque formation and rupture. In the process of atherosclerosis, oxidized low-density lipoprotein (oxLDL) upregulates MMP9 in human aortic vascular smooth muscle cells (HA/VSMCs). Adiponectin is an adipose tissue-derived hormone that has been shown to exert anti-atherogenic and anti-inflammatory effects. The aim of this study was to investigate the effect of adiponectin on MMP9 expression under pathogenic condition created by oxLDL in HA/VSMCs. METHODS: In this experimental study, HA/VSMC were stimulated with oxLDL alone and in the presence of adiponectin for 24 and 48 h. The expression of MMP9 gene was determined by real-time polymerase chain reaction method. The protein level of this gene was investigated by western blotting technique. RESULTS: An oxLDL increased MMP9 expression 2.16 +/- 0.24- and 3.32 +/- 0.25-fold after 24 and 48 h, respectively and adiponectin decreased oxLDL-induced MMP9 expression in a time-dependent manner. CONCLUSION: These results show that adiponectin changes extracellular matrix by reducing MMP9 mRNA and protein, therefore, may stabilize lesions and reduce atheroma rupture.
引用
收藏
页码:191 / 195
页数:5
相关论文
共 25 条
  • [1] Cardiac remodeling in obesity
    Abel, E. Dale
    Litwin, Sheldon E.
    Sweeney, Gary
    [J]. PHYSIOLOGICAL REVIEWS, 2008, 88 (02) : 389 - 419
  • [2] [Anonymous], INT J EPIDEMIOL, DOI DOI 10.1093/IJE/DYL098
  • [3] Ardans JA, 2002, J LEUKOCYTE BIOL, V71, P1012
  • [4] Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease
    Blankenberg, S
    Rupprecht, HJ
    Poirier, O
    Bickel, C
    Smieja, M
    Hafner, G
    Meyer, J
    Cambien, F
    Tiret, L
    [J]. CIRCULATION, 2003, 107 (12) : 1579 - 1585
  • [5] Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome
    Cheng, Min
    Hashmi, Satwat
    Mao, Xiaobo
    Zeng, Qiu Tang
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2008, 24 (05) : 385 - 390
  • [6] Adiponectin Induces Vascular Smooth Muscle Cell Differentiation via Repression of Mammalian Target of Rapamycin Complex 1 and FoxO4
    Ding, Min
    Xie, Yi
    Wagner, Robert J.
    Jin, Yu
    Carrao, Ana Catarina
    Liu, Lucinda S.
    Guzman, Anthony K.
    Powell, Richard J.
    Hwa, John
    Rzucidlo, Eva M.
    Martin, Kathleen A.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (06) : 1403 - U366
  • [7] Adipose tissue as an endocrine organ
    Galic, Sandra
    Oakhill, Jon S.
    Steinberg, Gregory R.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2010, 316 (02) : 129 - 139
  • [8] Mechanism of matrix metalloproteinase axis-induced neointimal growth
    Guo, Ling
    Ning, Wenhu
    Tan, Zhen
    Gong, Zhaowei
    Li, Xueqi
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2014, 66 : 116 - 125
  • [9] Guzik TJ, 2006, J PHYSIOL PHARMACOL, V57, P505
  • [10] Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome
    Hara, Kazuo
    Horikoshi, Momoko
    Yamauchi, Toshimasa
    Yago, Hirokazu
    Miyazaki, Osamu
    Ebinuma, Hiroyuki
    Imai, Yasushi
    Nagai, Ryozo
    Kadowaki, Takashi
    [J]. DIABETES CARE, 2006, 29 (06) : 1357 - 1362